Paclitaxel in the belly plus chemo vs chemo alone for stomach cancer spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard intravenous chemotherapy improves outcomes for people with stomach or esophageal cancer that has spread to the lining of the abdomen (peritoneal metastasis).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or lower esophageal cancer confirmed by biopsy
- Cancer has spread to the lining of your abdomen (confirmed by biopsy or fluid sample)
- You have had a laparoscopy (small camera surgery) to check the extent of spread within the last 4 weeks
- You are well enough to carry out daily activities (ECOG 0-1)
- You are at least 18 years old and expected to live at least 3 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for stomach cancer that has spread to the lining of the abdomen. The goal is to see if this approach can shrink or control the cancer, potentially making surgery possible.
This trial tests a new combination for advanced stomach cancer that has spread and caused fluid buildup in the belly (malignant ascites). It combines an immunotherapy drug (anti-PD-1) with standard chemotherapy and a targeted chemotherapy given directly into the belly to see if it can shrink the cancer and help you feel better.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial studies whether adding paclitaxel chemotherapy around the time of surgery can improve outcomes for people with stomach or gastroesophageal junction adenocarcinoma that has spread to the lining of the abdomen (peritoneum). It targets cancers confirmed by testing of belly fluid or by laparoscopy/laparotomy, and may help by treating cancer cells right at the time of surgery.
This study tests a treatment that combines chemotherapy given directly into the abdomen (intraperitoneal) with standard systemic chemotherapy for people whose gastrointestinal cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). It aims to control the cancer and improve how patients feel.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
Hear when a new Gastric Cancer Peritoneal Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.